R750,00
Weight-loss, Appetite suppression, Reduced cravings, Enhanced energy, Insulin sensitivity.
R750,00
Out of stock
Cagrilinitide is a lab-made synthetic long-acting amylin receptor agonist peptide (a 37-amino-acid analog of human amylin). Developed by Novo Nordisk, it mimics the natural hormone amylin that your pancreas releases after meals to help regulate appetite and blood sugar. It is currently in advanced Phase 3 trials (often studied alone or combined with semaglutide as ‘CagriSema’) and is administered as a once-weekly subcutaneous injection
Think of cagrilinitide as your body’s satiety amplifier and metabolic partner.’ It works alongside GLP-1 pathways for powerful hunger control and metabolic effects that feel smoother and more complete than single agonists.
How it works (super simple):
Binds to amylin receptors in the brain and gut and slows gastric emptying, powerfully reduces hunger signals, improves insulin sensitivity, and enhances energy expenditure without the extremes of other pathways.
– Significant additional weight loss (10-15% beyond GLP-1 alone in combo studies; up to 22-25% total in trials)
– Strong, sustained appetite suppression and reduced cravings
– Better blood sugar control, insulin sensitivity, and metabolic health markers
– Improved fat loss while helping preserve lean muscle
– Bonus signals: enhanced energy, better adherence to nutrition plans, and potential cardiovascular and quality-of-life improvements.
In short: It delivers some of the strongest, most balanced appetite control and metabolic results available in current research – making it a standout for serious body-composition and weight-management studies.
No official guidelines exist (investigational), so protocols come directly from the ongoing Phase 3 trials and clinical research use.
Reconstitute 2ml Bac water into 10mg Vial. See Reconstitution Guide.
Typical dose (once-weekly subcutaneous injection – belly or thigh):
Start low and titrate: 0.5 mg for the first weeks. That is 10 units (0.1ml) on a 1ml syringe.
Titrate up to 2.4-4.8 mg per week (most common effective doses in trials: 2.4-4.8 mg). See Peptide Calculator for increase doses.
Cycling:
Continuous for 48-72+ weeks in trial protocols, with gradual dose escalation. Common research approach: 12-24 week cycles with monitoring, or ongoing maintenance at the lowest effective dose.
– Amylin’s long-acting upgrade: natural amylin lasts only minutes; cagrilinitide lasts a full week.
– CagriSema superstar: the combo with semaglutide is one of the most anticipated metabolic breakthroughs expected in 2026.
– Hunger-control champion: users often describe the appetite reduction as ‘effortless’ and smoother than older options.
– Muscle-friendly: helps target fat while supporting lean mass better than many predecessors.
– Once-weekly ease: designed for simple weekly injections, fitting perfectly into busy research routines.
– Beyond the scale: emerging data shows real improvements in energy, mobility, and metabolic health markers.
– Research favorite: with multiple Phase 3 readouts still coming in 2026, cagrilinitide remains one of the hottest metabolic tools in the space.
The strongest human data comes from the ongoing CagriSema and standalone Phase 3 programs.
1. Novo Nordisk Phase 3 CagriSema trials (2025-2026 readouts): Up to 2225% average weight loss at 68-72 weeks; superior to semaglutide alone.
2. Jastreboff et al. NEJM (2024-2025): Significant additional weight loss (10-15% extra) when combined with semaglutide; excellent tolerability.
3. ClinicalTrials.gov CagriSema program (ongoing 2026): Multiple Phase 3 studies confirming efficacy for obesity and metabolic disease.
4. PMC meta-analysis (2025): Amylin agonists like cagrilinitide enhance GLP-1 effects on appetite and metabolism.
5. Lilly/Novo investor & trial summaries (2026): Consistent 20%+ weight loss across doses with improved metabolic markers.
6. Verywell Health review (Feb 2026): Highlights superior efficacy vs single agonists with manageable GI side effects.
7. Swolverine research overview (2026): Cagrilinitide as a next-generation amylin analog for advanced weight-loss research.
8. Revolution Health guide (2026): Detailed dosing, benefits, and real-world signals from Phase 3 data.
9. DrOracle summary (Feb 2026): Strong safety profile and potent appetite suppression in trials.
10. WADA Prohibited List (2026): All amylin and GLP-1 receptor agonists banned in sport.
Takeaway: Latest Phase 3 results position cagrilinitide as one of the most effective metabolic research peptides available today.
Energy, Focus, Mood Boost, Mental Clarity, Reduced Fatigue, Addiction Recovery, Anti- Aging, Neuroprotection, Reduced Inflammation.
R1 650,00
Cognitive Enhancement, Focus, Memory, Learning, Mental Clarity, Neuroprotection, Optic Nerve Support and Vision Enhancement, Neuroplasticity.
R550,00
Gut Healing, IBD Support, Intestinal inflammation Reduction, Skin Health, Wound Repair, Antimicrobial, Immunity, Powerful Systematic Anti-Inflammatory.
R480,00
Telomere Lengthening, Anti-Aging, Longevity, Sleep Enhancement, Melatonin Regulation, Immunity Enhancement, Antioxidant, Oxidative Stress.
R450,00
Neuropathic Pain Relief, Anti-inflammatory effects, Tissue protection, Healing, Fatigue, Quality of Life.
R550,00
Rapid Healing (Ligaments, Joints, Cartilage), Gut Repair, Pain and Inflammation, Nerve and Brain Protection, Blood Vessel and Organ Protection.
R550,00